Total Payments
$12,860
2024 Payments
$2,591
Companies
76
Transactions
725
Medicare Patients
27,989
Medicare Billing
$6.8M
Payment Breakdown by Category
Food & Beverage$12,398 (96.4%)
Education$462.31 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,398 | 714 | 96.4% |
| Education | $462.31 | 11 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,617 | 99 | $0 (2024) |
| Genentech USA, Inc. | $794.36 | 50 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $746.36 | 58 | $0 (2024) |
| PFIZER INC. | $725.10 | 70 | $0 (2024) |
| Janssen Biotech, Inc. | $724.40 | 40 | $0 (2024) |
| Merck Sharp & Dohme LLC | $520.45 | 30 | $0 (2024) |
| Nevro Corp. | $446.52 | 3 | $0 (2018) |
| Amgen Inc. | $444.44 | 26 | $0 (2023) |
| Astellas Pharma US Inc | $423.85 | 23 | $0 (2024) |
| Incyte Corporation | $325.86 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,591 | 127 | Novartis Pharmaceuticals Corporation ($202.21) |
| 2023 | $2,129 | 102 | Novartis Pharmaceuticals Corporation ($287.54) |
| 2022 | $1,646 | 89 | Novartis Pharmaceuticals Corporation ($311.91) |
| 2021 | $239.61 | 10 | Incyte Corporation ($98.95) |
| 2020 | $236.05 | 15 | Novartis Pharmaceuticals Corporation ($69.09) |
| 2019 | $1,618 | 108 | Merck Sharp & Dohme Corporation ($176.51) |
| 2018 | $2,369 | 138 | Nevro Corp. ($446.52) |
| 2017 | $2,032 | 136 | Novartis Pharmaceuticals Corporation ($264.90) |
All Payment Transactions
725 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $77.97 | General |
| 12/17/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Oncology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $33.91 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $8.93 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY | Food and Beverage | In-kind items and services | $1.22 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: HEMATOLOGY | ||||||
| 12/05/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/03/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Immunology | ||||||
| 11/22/2024 | PFIZER INC. | BOSULIF (Drug) | Education | In-kind items and services | $11.33 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/22/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $10.48 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $22.61 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $9.78 | General |
| Category: Oncology | ||||||
| 11/13/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq, Tecentriq Hybreza | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: BioOncology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.30 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: Oncology | ||||||
| 10/30/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Gazyva (Biological), Venclexta | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: BioOncology | ||||||
| 10/22/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 46 | 4,388 | 156,871 | $4.3M | $1.2M |
| 2022 | 70 | 6,987 | 165,795 | $4.8M | $1.4M |
| 2021 | 81 | 8,700 | 202,973 | $5.9M | $1.7M |
| 2020 | 84 | 7,914 | 215,291 | $7.8M | $2.6M |
Total Patients
27,989
Total Services
740,930
Medicare Billing
$6.8M
Procedure Codes
281
All Medicare Procedures & Services
281 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 11,400 | $1.6M | $483,937 | 31.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 51 | 11,280 | $575,280 | $206,050 | 35.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 445 | 1,186 | $402,054 | $111,021 | 27.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 53 | 13,180 | $303,140 | $77,714 | 25.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 99 | 415 | $156,870 | $39,959 | 25.5% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 19 | 2,200 | $125,400 | $37,506 | 29.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 314 | 434 | $103,726 | $26,694 | 25.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 69 | 64,770 | $259,080 | $25,531 | 9.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 849 | 2,899 | $26,091 | $24,343 | 93.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 837 | 2,974 | $86,246 | $22,611 | 26.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 110 | 348 | $65,772 | $16,413 | 25.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 14 | 18,750 | $56,250 | $16,116 | 28.7% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 29 | 10,400 | $52,000 | $14,244 | 27.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 66 | 224 | $44,128 | $13,835 | 31.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 71 | 85 | $47,260 | $11,664 | 24.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 81 | $45,522 | $11,165 | 24.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 89 | 89 | $40,203 | $10,287 | 25.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 180 | 800 | $55,200 | $8,335 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 58 | $27,492 | $7,887 | 28.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 124 | 487 | $29,707 | $5,643 | 19.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 32 | 91 | $16,198 | $4,443 | 27.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 64 | 203 | $17,052 | $4,295 | 25.2% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 82 | 139 | $21,684 | $3,705 | 17.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 35 | 149 | $11,771 | $3,190 | 27.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 26 | 199 | $11,144 | $3,084 | 27.7% |
About Dr. Christopher Alexander, DO
Dr. Christopher Alexander, DO is a Hematology healthcare provider based in Ormond Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306850508.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Alexander, DO has received a total of $12,860 in payments from pharmaceutical and medical device companies, with $2,591 received in 2024. These payments were reported across 725 transactions from 76 companies. The most common payment nature is "Food and Beverage" ($12,398).
As a Medicare-enrolled provider, Alexander has provided services to 27,989 Medicare beneficiaries, totaling 740,930 services with total Medicare billing of $6.8M. Data is available for 4 years (2020–2023), covering 281 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Ormond Beach, FL
- Active Since 07/27/2006
- Last Updated 08/01/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1306850508
Products in Payments
- OPDIVO (Biological) $567.25
- KISQALI (Drug) $459.19
- Senza Spinal Cord Stimulation System (Device) $446.52
- IMBRUVICA (Drug) $404.00
- KEYTRUDA (Biological) $379.76
- PROMACTA (Drug) $370.49
- DARZALEX (Biological) $300.37
- JEVTANA (Drug) $256.48
- Lenvima (Drug) $247.53
- IBRANCE (Drug) $234.98
- XTANDI (Drug) $233.81
- GAZYVA (Biological) $178.24
- JAKAFI (Drug) $177.72
- MEKINIST (Drug) $166.02
- TECENTRIQ (Biological) $160.70
- Kyprolis (Biological) $159.51
- LIBTAYO (Biological) $156.54
- Zoladex (Drug) $153.93
- ZEJULA (Drug) $151.08
- MONJUVI (Drug) $148.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.